DNTH insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 100% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 8 officers and directors who sold. 12 are left out

Left out: Simrat Randhawa, Anne McGeorge, Alison Lawton, Ryan Savitz, Jonathan Violin, Edward Carr, Adam Veness, Marino Garcia, Paula Soteropoulos, Steven Romano, Sujay Kango and Simon Read (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Marino Garcia

CEO and President, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$28.0MDisclosed plan

Simrat Randhawa

EVP, Head of R&D

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$15.0MDisclosed plan

Ryan Savitz

EVP, CFO & Cbo

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$14.3MDisclosed plan

Edward Carr

Chief Accounting Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.6MDisclosed plan

Adam Veness

SVP, General Counsel and Sec.

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.6MDisclosed plan

All 8 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 17, 2026Edward Carr sold 20K shares ($2.0M) under a disclosed trading plan. 20K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Edward Carr Chief Accounting Officer	20,000	$101.38	n/a	n/a	Sep 17, 2026	Sep 18, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Dianthus Therapeutics, Inc. CEO selling stock?

Yes. Marino Garcia sold 289K shares ($28.0M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Dianthus Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.

Are any Dianthus Therapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold8 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Marino Garcia CEO and President, Director	$28.0M 289K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Simrat Randhawa EVP, Head of R&D	$15.0M 280K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Ryan Savitz EVP, CFO & Cbo	$14.3M 174K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Edward Carr Chief Accounting Officer	$5.6M 64K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Adam Veness SVP, General Counsel and Sec.	$4.6M 50K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Paula Soteropoulos Director	$2.3M 29K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Anne McGeorge Director	$845K 7.8K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Simon Read Director	$631K 5.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 12 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Simrat Randhawa

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Simrat Randhawa are complete.

EVP, Head of R&D

n/a

−280K

n/a

Vesting, gifts, unvested awards and holding lines for Simrat Randhawa

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Simrat Randhawa are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
56,776	$17.88	Jan 23, 2034	$4.9M
41,676	$21.77	May 22, 2034	$3.4M
87,500	$22.07	Feb 2, 2035	$7.2M
60,000	$37.87	Sep 23, 2035	$4.0M
150,000	$52.46	Feb 3, 2036	$7.8M

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Anne McGeorge

Director

n/a

−7.8K

n/a

Vesting, gifts, unvested awards and holding lines for Anne McGeorge

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Anne McGeorge are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,000	$21.77	May 22, 2034	$909K
12,500	$18.36	May 22, 2035	$1.1M
6,090	$89.63	May 21, 2036	$90K

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Alison Lawton

Director

n/a

Vesting, gifts, unvested awards and holding lines for Alison Lawton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alison Lawton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,000	$21.77	May 22, 2034	$909K
12,500	$18.36	May 22, 2035	$1.1M
6,090	$89.63	May 21, 2036	$90K

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Ryan Savitz

EVP, CFO & Cbo

n/a

−174K

n/a

Vesting, gifts, unvested awards and holding lines for Ryan Savitz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ryan Savitz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
71,776	$17.88	Jan 23, 2034	$6.2M
68,751	$21.77	May 22, 2034	$5.7M
150,000	$22.07	Feb 2, 2035	$12.3M
104,766	$8.44	Jun 6, 2032	$10.1M
60,000	$37.87	Sep 23, 2035	$4.0M
10,399	$8.44	Jun 6, 2032	$998K
150,000	$52.46	Feb 3, 2036	$7.8M

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Jonathan Violin

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jonathan Violin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Violin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,000	$21.77	May 22, 2034	$909K
12,500	$18.36	May 22, 2035	$1.1M
6,090	$89.63	May 21, 2036	$90K

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Edward Carr

Chief Accounting Officer

n/a

−64K

n/a

Vesting, gifts, unvested awards and holding lines for Edward Carr

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Edward Carr are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
43,818	$17.88	Jan 23, 2034	$3.8M
50,000	$21.77	May 22, 2034	$4.1M
42,500	$22.07	Feb 2, 2035	$3.5M
55,000	$52.46	Feb 3, 2036	$2.9M

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Adam Veness

SVP, General Counsel and Sec.

n/a

−50K

n/a

Vesting, gifts, unvested awards and holding lines for Adam Veness

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adam Veness are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
60,000	$17.88	Jan 23, 2034	$5.2M
75,000	$21.77	May 22, 2034	$6.2M
100,000	$22.07	Feb 2, 2035	$8.2M
100,000	$52.46	Feb 3, 2036	$5.2M
73,240	$18.17	Jun 28, 2033	$6.3M

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Marino Garcia

CEO and President, Director

n/a

−289K

n/a

Vesting, gifts, unvested awards and holding lines for Marino Garcia

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Marino Garcia are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
41	$6.70	Nov 3, 2031	$4K
160,004	$8.44	Jun 6, 2032	$15.4M
269,408	$17.88	Jan 23, 2034	$23.3M
243,000	$21.77	May 22, 2034	$20.1M
340,000	$22.07	Feb 2, 2035	$28.0M
120,000	$39.35	Sep 30, 2035	$7.8M
355,000	$52.46	Feb 3, 2036	$18.4M

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Paula Soteropoulos

Director

n/a

−29K

n/a

Vesting, gifts, unvested awards and holding lines for Paula Soteropoulos

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Paula Soteropoulos are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,000	$21.77	May 22, 2034	$909K
12,500	$18.36	May 22, 2035	$1.1M
6,090	$89.63	May 21, 2036	$90K

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Steven Romano

Director

n/a

Vesting, gifts, unvested awards and holding lines for Steven Romano

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Steven Romano are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,000	$26.42	Sep 15, 2034	$1.7M
12,500	$18.36	May 22, 2035	$1.1M
6,090	$89.63	May 21, 2036	$90K

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Sujay Kango

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sujay Kango

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sujay Kango are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,000	$19.86	Mar 4, 2035	$2.1M
6,090	$89.63	May 21, 2036	$90K

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Simon Read

Director

n/a

−5.6K

n/a

Vesting, gifts, unvested awards and holding lines for Simon Read

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Simon Read are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,445	$18.36	May 22, 2035	$1.7M
6,090	$89.63	May 21, 2036	$90K

Estimate: options held × ($104.39 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Holdings and share of stake for Dianthus Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$71.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $71.2M across 898,559 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $71.2M · 100%

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Marino Garcia CEO and President, Director	289K	$28.0M	100%	39%	Mar 12, 2026 to Aug 7, 2026
Simrat Randhawa EVP, Head of R&D	280K	$15.0M	100%	21%	Nov 13, 2025 to Sep 1, 2026
Ryan Savitz EVP, CFO & Cbo	174K	$14.3M	100%	20%	Dec 4, 2025 to Jul 9, 2026
Edward Carr Chief Accounting Officer	64K	$5.6M	100%	8%	Mar 12, 2026 to Sep 17, 2026
Adam Veness SVP, General Counsel and Sec.	50K	$4.6M	100%	7%	Jun 17, 2026 to Aug 10, 2026
Paula Soteropoulos Director	29K	$2.3M	100%	3%	Mar 24, 2026 to May 8, 2026
Anne McGeorge Director	7.8K	$845K	100%	1%	Aug 10, 2026 to Aug 10, 2026
Simon Read Director	5.6K	$631K	100%	0.9%	Aug 10, 2026 to Aug 19, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$7.4M	$7.4M	$0	$0
Dec 2025	$904K	$904K	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$28.0M	$28.0M	$0	$0
Apr 2026	$739K	$739K	$0	$0
May 2026	$51K	$51K	$0	$0
Jun 2026	$4.8M	$4.8M	$0	$0
Jul 2026	$3.2M	$3.2M	$0	$0
Aug 2026	$21.6M	$21.6M	$0	$0
Sep 2026	$4.5M	$4.5M	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $71.2M sold, after almost none in the past 5 years. 8 insiders sold; the average is 2 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	899K	8	$71.2M
Oct 13, 2025 1 year earlier	20K	1	$700K
Oct 13, 2024 2 years earlier	0	0	$0
Oct 14, 2023 3 years earlier	0	0	$0
Oct 14, 2022 4 years earlier	0	0	$0
Oct 14, 2021 5 years earlier	50K	7	$334K

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty12 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Dianthus Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology289 filings on record, 34 filed in the 12-month period, and how we read them

All 289 Forms 3, 4 and 5 on record for Dianthus Therapeutics, Inc. (SEC CIK 1690585), filed from Jun 20, 2018 to Sep 18, 2026; 34 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (33)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Fairmount Funds Management LLC	Oct 1, 2024	4,544,524 shares, last reported balance as of Sep 27, 2024
Leon Moulder Jr.	May 28, 2024	1,436,745 shares, last reported balance as of Jan 22, 2024
Lei Meng	Jan 24, 2024	2,717,554 shares, last reported balance as of Jan 22, 2024
Lei Meng	Jan 24, 2024	No balance on record
Third Rock Ventures IV, L.P.	Feb 9, 2023	3,058,204 shares, last reported balance as of Feb 8, 2023
Jason Gardner	Dec 2, 2022	944,954 shares, last reported balance as of Nov 30, 2022
Kristen Stants	Dec 2, 2022	20,264 shares, last reported balance as of Nov 30, 2022
Stephen Mahoney	Dec 2, 2022	17,264 shares, last reported balance as of Nov 30, 2022
Thomas Beetham	Dec 2, 2022	19,897 shares, last reported balance as of Nov 30, 2022
Caren Deardorf	Dec 2, 2022	19,762 shares, last reported balance as of Nov 30, 2022
Michael Vasconcelles	Aug 17, 2022	No balance on record
Lisa Olson	Aug 1, 2022	14,264 shares, last reported balance as of Sep 16, 2021
David Nichols	Aug 1, 2022	14,306 shares, last reported balance as of Sep 16, 2021
Jeffrey Humphrey	Aug 1, 2022	No balance on record
Jeffrey Albers	Jun 30, 2022	4,152 shares, last reported balance as of Jun 25, 2018
Thomas Daniel	Jun 30, 2022	101,926 shares, last reported balance as of Jun 25, 2018
Amy Ronneberg	Jun 30, 2022	593,611 shares, last reported balance as of Jun 25, 2018
Bruce Booth	Jun 30, 2022	No balance on record
David Scadden	Jun 30, 2022	808,674 shares, last reported balance as of Jun 25, 2018
Bruce Booth	Jun 30, 2022	9,484,250 shares, last reported balance as of Jun 29, 2020
Alexis Borisy	Sep 23, 2021	4,100 shares, last reported balance as of Aug 26, 2021
Michael Bonney	Jun 3, 2021	65,346 shares, last reported balance as of Feb 27, 2019
John Davis Jr.	Feb 16, 2021	8,304 shares, last reported balance as of Jan 2, 2020
Atlas Venture Fund X, L.P.	Feb 16, 2021	3,148,399 shares, last reported balance as of Feb 11, 2021
Zoran Zdraveski	Feb 16, 2021	128,009 shares, last reported balance as of Dec 24, 2019
Cindy Driscoll	Oct 13, 2020	No balance on record
Atlas Venture Opportunity Fund I, L.P.	Jul 13, 2020	1,250,000 shares, last reported balance as of Jun 29, 2020
Blake Byers	Jun 9, 2020	No balance on record
Blake Byers	Jun 9, 2020	3,339,137 shares, last reported balance as of Jun 25, 2018
Christina Isacson	Feb 12, 2020	83,786 shares, last reported balance as of Dec 24, 2019
Jason Ryan	Feb 12, 2020	No balance on record
Michael Cooke	Dec 2, 2019	240,523 shares, last reported balance as of Dec 2, 2019
GV 2016 GP, L.L.C.	Jun 27, 2018	3,339,137 shares, last reported balance as of Jun 25, 2018

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Dianthus Therapeutics, Inc. insiders sold $71.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Dianthus Therapeutics, Inc. CEO selling stock?

Why are Dianthus Therapeutics, Inc. insiders selling?

Are any Dianthus Therapeutics, Inc. insiders buying?

The evidence

Sales by month